Organisation › Details

MolMed S.p.A. (MLMD.MI)

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, is looking forward to obtain the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the field of innovative oncological therapies MolMed pipeline also includes NGR-hTFN, a therapeutic agent for the treatment of solid tumors. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. *

 

Period Start 1996-01-01 established
  Predecessor San Raffaele Scientific University Institute
Products Industry gene therapy
  Industry 2 cell therapy
Persons Person Palmisano, Riccardo (MolMed 201606 CEO)
  Person 2 Calabrese, Salvatore (MolMed 201809– CFO before Gentium CFO 2005–2014 + Novopharma SpA + PriceWaterhouseCoopers)
     
Region Region Milano (Milan)
  Country Italy
  Street 58 via Olgettina
  City 20132 Milan
  Tel +39-02-21277-1
    Address record changed: 2013-05-16
     
Basic data Employees n. a.
     
    * Document for �About Section�: MolMed S.p.A.. (3/13/19). "Press Release: Partnership in the Field of Rare Genetic Diseases with Rocket Pharma Extended to Three New Therapeutic Indications". Milan.
     
   
Record changed: 2019-06-09

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

More documents for MolMed S.p.A. (MLMD.MI)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] – Putting Information into Context 600x60px




» top